CNS Pharmaceuticals annual capital expenditures (capex)
2018
2019
2020
2021
2022
2023
2024
2025
CNS Pharmaceuticals Capital Expenditures (CapEx) Growth & History (CNSP)
CNS Pharmaceuticals's capital expenditures (capex) was $18,175 for fiscal 2025.
View full CNS Pharmaceuticals company overviewCNS Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18,175 | $13,987 | +333.98% |
| 2024 | 2024-12-31 | $4,188 | $287 | +7.36% |
| 2023 | 2023-12-31 | $3,901 | −$521 | −11.78% |
| 2022 | 2022-12-31 | $4,422 | −$1,326 | −23.07% |
| 2021 | 2021-12-31 | $5,748 | −$12,197 | −67.97% |
| 2020 | 2020-12-31 | $17,945 | −$2,175 | −10.81% |
| 2019 | 2019-12-31 | $20,120 | $20,120 | — |
| 2018 | 2018-12-31 | $0 | — | — |
CNS Pharmaceuticals quarterly capital expenditures (capex)
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q3.23
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3,821 | $3,821 | — |
| Q1 2026 | 2026-03-31 | $6,179 | $6,179 | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $1,744 | $230 | +15.19% |
| Q4 2022 | 2022-12-31 | $1 | −$2,075 | −99.95% |
| Q3 2022 | 2022-09-30 | $1,514 | $1,514 | — |
| Q2 2022 | 2022-06-30 | $2,909 | $2,909 | — |
| Q1 2022 | 2022-03-31 | $0 | −$3,672 | — |
| Q4 2021 | 2021-12-31 | $2,076 | $2,076 | — |
| Q3 2021 | 2021-09-30 | $0 | $0 | — |
| Q2 2021 | 2021-06-30 | $0 | −$11,535 | — |
| Q1 2021 | 2021-03-31 | $3,672 | −$2,738 | −42.71% |
| Q4 2020 | 2020-12-31 | $0 | −$11,743 | — |
| Q3 2020 | 2020-09-30 | $0 | $0 | — |
| Q2 2020 | 2020-06-30 | $11,535 | $3,158 | +37.70% |
| Q1 2020 | 2020-03-31 | $6,410 | $6,410 | — |
| Q4 2019 | 2019-12-31 | $11,743 | — | — |
| Q3 2019 | 2019-09-30 | $0 | — | — |
| Q2 2019 | 2019-06-30 | $8,377 | — | — |
| Q1 2019 | 2019-03-31 | $0 | — | — |
CNS Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, CNS Pharmaceuticals's capital expenditures (capex) increased from $17,945 to $18,175, a change of $230. The latest reported quarter, Q2 2026, shows $3,821.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CNS Pharmaceuticals source filings ↗